Misfolded SOD1 Immunoassay for ALS Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring amyotrophic lateral sclerosis (ALS) lack effective biomarkers for early detection, disease progression, and treatment efficacy, particularly for sporadic ALS, due to the complexity of the disease and limited sensitivity of existing assays for misfolded SOD1 in cerebrospinal fluid.
Innovation Solution
A novel highly sensitive immunoassay using specific anti-SOD1 antibodies, such as NI-204.B and NI-204.O, which recognize a particular epitope of SOD1, enabling reliable detection of misfolded SOD1 in body fluids, particularly cerebrospinal fluid, to differentiate ALS patients from controls and monitor disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunoassay methods are used for detecting SOD1 in cerebrospinal fluid, then the assay can be performed with standard reagents, but the sensitivity is insufficient to reliably detect misfolded SOD1 at low concentrations in ALS patients
Solution Approach 1:
The patent applies parameter changes by modifying the antibody reagents used in the immunoassay. Specifically, it employs a capture antibody (NI-204.B) and detection antibody (NI-204.O) pair that specifically recognizes misfolded SOD1 conformation, thereby changing the binding affinity and specificity parameters to achieve detection at low concentrations (pg/mL range) that were not achievable with conventional antibodies
Solution Approach 2:
The patent uses misfolded SOD1-specific antibodies as intermediaries to detect the presence and concentration of misfolded SOD1 in cerebrospinal fluid. These antibodies act as mediators that bridge the detection system and the target analyte, enabling sensitive detection through their specific conformational recognition capability
2Reliability
If existing biomarkers are used for ALS diagnosis, then the diagnostic process can proceed with available markers, but the ability to differentiate ALS from control populations and monitor disease progression is insufficient
Solution Approach 1:
The patent applies local quality by focusing on a specific conformational epitope of SOD1 that is exposed or altered only in the misfolded state. The antibodies NI-204.B and NI-204.O are designed to recognize this specific local structural feature, providing high specificity for misfolded SOD1 while maintaining the ability to detect it across different ALS contexts (sporadic and familial cases)
3Measurement precision
If high sensitivity detection of misfolded SOD1 is achieved, then early diagnosis and treatment monitoring can be improved, but the assay complexity and requirements for specific antibodies increase
Solution Approach 1:
The patent applies universality by developing an immunoassay system that can serve multiple functions: detecting misfolded SOD1 in cerebrospinal fluid, quantifying its concentration, differentiating ALS patients from controls, and monitoring disease progression. The antibody pair (NI-204.B capture antibody and NI-204.O detection antibody) is designed to be universally applicable across different ALS subtypes and clinical scenarios, reducing the need for multiple specialized assays
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoassay provides a high degree of certainty in identifying ALS patients, including sporadic cases, and allows for precise quantification of low mSOD1 concentrations, aiding in treatment optimization and clinical trial assessments.
Implementation Method 1
using an immunoassay comprising an anti-SOD1 antibody as capture antibody, which is directed to a specific epitope of SOD1
Data Source
AI summary
Provided is a novel high sensitive method for assaying misfolded SOD1 in a body fluid of a subject, in particular in the cerebrospinal fluid. This method is based on a novel highly sensitive immunoassay making use of a unique epitope of SOD1 and corresponding anti-SOD1 antibodies. In addition, kits comprising the components of the immunoassay are provided.